Aderis Pharmaceuticals announced today that Chairman, President and Chief Executive Officer, Peter Savas, will present a corporate overview on Wednesday, February 26 at 2:30 p.m. (EST) during the Biotechnology Industry Organization’s annual BIO CEO & Investor Conference. The conference will take place February 25–27 at the Waldorf=Astoria hotel in New York City and will feature presentations from leading biotechnology companies and investors shaping the future investment landscape of the biotechnology industry.Aderis Pharmaceuticals is a biopharmaceutical company engaged in small molecule drug development to treat central nervous system, cardiovascular and renal disorders. The Company currently has four product candidates in six clinical development programs. Aderis Pharmaceuticals has a strategic alliance with Schwarz Pharma AG, which develops rotigotine CDS, a dopamine agonist for the treatment of Parkinson’s disease using a proprietary, once-a-day, continuous delivery transdermal patch, currently in Phase III trials. The Company also has alliances with Fujisawa Healthcare, Inc. and King Pharmaceuticals. Aderis Pharmaceuticals’ product pipeline includes receptor agonists and antagonists for the diagnosis and treatment of Parkinson’s disease, Restless Legs Syndrome, atrial fibrillation, coronary artery disease and wound healing in diabetic foot ulcers. Founded in 1994, Aderis Pharmaceuticals is headquartered in Hopkinton, Massachusetts and has research facilities in Richmond, Virginia.
Certain statements in this news release that are not historical fact constitute “forward-looking statements.” Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results of Aderis Pharmaceuticals to be materially different from historical results or from any results expressed or implied by such forward-looking statements. Such statements include, but are not limited to, any statements relating to the Company’s development programs and any other statements that are not historical facts. Such statements involve risks and uncertainties, including but not limited to, those risks and uncertainties relating to difficulties or delays in development, testing, regulatory approval, production and marketing of the Company’s drug candidates; unexpected adverse side effects or inadequate therapeutic efficacy of the Company’s drug candidates that could slow or prevent product development or commercialization; the uncertainty of patent protection for the Company’s intellectual property or trade secrets; and the Company’s ability to obtain additional financing if necessary. Such statements are based on management’s current expectations, but actual results may differ materially due to various factors, some but not all of which may have been mentioned above.
back to top
